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The growth-stimulating effects of thrombin are medi-
ated primarily via activation of a G protein-coupled re-
ceptor, PAR-1. Because PAR-1 has no intrinsic tyrosine
kinase activity, yet requires tyrosine phosphorylation
events to induce mitogenesis, we investigated the role of
the Janus tyrosine kinases (JAKs) in thrombin-medi-
ated signaling. JAK2 was activated rapidly in rat vascu-
lar smooth muscle cells (VSMC) treated with thrombin,
and signal transducers and activators of transcription
(STAT1 and STAT3) were phosphorylated and translo-
cated to the nucleus in a JAK2-dependent manner. AG-
490, a JAK2-specific inhibitor, and a dominant negative
JAK2 mutant inhibited thrombin-induced ERK2 activity
and VSMC proliferation suggesting that JAK2 is up-
stream of the Ras/Raf/MEK/ERK pathway. To elucidate
the functional significance of JAK-STAT activation, we
studied the effect of thrombin on heat shock protein
(Hsp) expression, based upon the following: 1) reports
that thrombin stimulates reactive oxygen species pro-
duction in VSMC; 2) the putative role of Hsps in modu-
lating cellular responses to reactive oxygen species; and
3) the presence of functional STAT1/3-binding sites in
Hsp70 and Hsp90b promoters. Indeed, thrombin up-reg-
ulated Hsp70 and Hsp90 protein expression via en-
hanced binding of STATs to cognate binding sites in the
Hsp70 and Hsp90 promoters. Together, these results
suggest that JAK-STAT pathway activation is necessary
for thrombin-induced VSMC growth and Hsp gene
expression.
In addition to regulating hemostasis and thrombosis, the
serine protease thrombin also promotes the inflammatory
response and wound healing (1) where it is mitogenic for
lymphocytes, fibroblasts, vascular endothelial and smooth
muscle cells (2–4). Many of the functions of thrombin are
mediated via activation of protease-activated receptor(s),
PAR-1, PAR-3, or PAR-4 (5–7). Thrombin cleaves the N ter-
minus of its PAR-1 receptor between Arg41 and Ser42 to
create a new N terminus 42SFLLRN47 that acts as a tethered
ligand and activates the receptor (5). Increased Ser/Thr ki-
nase activity in response to the stimulation of PAR-1 and
other G protein-coupled receptors is well demonstrated (8–
10). Thrombin also stimulates the expression of nuclear pro-
teins that constitute the transcription factor AP-1, which
participates in transactivation of several early growth re-
sponse genes implicated in VSMC1 proliferation (9, 11).
PAR-1, angiotensin II (Ang II) receptor, and other G pro-
tein-coupled receptors, which do not themselves possess in-
trinsic tyrosine kinase activity, require tyrosine kinase activ-
ity to induce mitogenesis (8, 12–14). These observations
suggest that G protein-coupled receptors may utilize cyto-
plasmic protein tyrosine kinases such as Janus kinases
(JAKs) and Src kinases to initiate mitogenesis. In fact, both
JAK and Src kinases play important roles in VSMC prolifer-
ation induced by Ang II (10, 15).
JAKs are 1 of 11 mammalian nonreceptor tyrosine kinase
families that were initially identified as essential mediators of
cellular signaling induced by the interaction of cytokines with
their cognate receptors (16). There are four members of the
JAK family, JAK1, JAK2, JAK3, and TYK2. Targeted gene
disruption studies in mice demonstrate that JAKs are essential
for cytokine-induced signaling (17, 18). In interactions of cyto-
kines with their cognate receptors, receptor dimerization in-
duced by ligand binding to cell surface receptors leads to the
activation of one or more of the JAK family of kinases associ-
ated with the transmembrane receptor. This, in turn, leads to
phosphorylation of tyrosine residues in the receptor cytoplas-
mic domains, which provide docking sites for signal transduc-
ers and activators of transcription (STATs) and other proteins
that contain phosphotyrosine-binding motifs (19). STATs, upon
phosphorylation by JAKs on tyrosine residues, undergo homo-
or heterodimerization with other STAT family members and
migrate to the nucleus. Within the nucleus, STAT dimers bind
to target genes to enhance transcription (20, 21). In addition to
tyrosine phosphorylation, STAT proteins undergo serine phos-
phorylation in a mitogen-activated protein kinase (MAP kinase)-
dependent manner. In fact, both serine and tyrosine phospho-
rylation of STAT proteins is necessary for maximal activation
of transcription (22, 23). Activation of STAT proteins has been
reported in cells treated with various cytokines, growth factors,
insulin, and Ang II (24–26).
Heat shock proteins (Hsps), initially identified by their en-
hanced synthesis in cells exposed to elevated temperatures,
have been subsequently shown to accumulate in response to
various stresses including cardiac hypertrophy, ischemic pre-
conditioning, oxidative stress, and aging (27). Expressed con-
stitutively, Hsps function as molecular chaperones under phys-
iologic conditions. During stress, Hsps prevent protein
aggregation, either through refolding of denatured proteins or
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by promoting their degradation through a proteolytic pathway
(28). Induction of Hsps on exposure to a stressor confers pro-
tection against exposure to a subsequent stressor in various
cell types (29, 30). Overexpression of individual Hsps also pro-
tects against thermal and ischemic stress and apoptosis (31,
32). Hsps may also regulate stress-responsive signaling path-
ways such as activation of c-Jun N-terminal kinase1 (JNK1)
and p38 (33). Induction of several Hsps has been reported in
VSMC (34) and may contribute to VSMC proliferation leading
to the onset of vascular diseases such as atherosclerosis.
Because thrombin-activated PAR-1 requires tyrosine phos-
phorylation events to induce mitogenesis, we investigated the
effect of thrombin on the activation of members of the JAK
family and their substrates, STATs. We show that thrombin
causes activation of JAK2 and tyrosine phosphorylation and
nuclear translocation of STAT1, -2, and -3. We also demon-
strate that inhibition of JAK2 activity attenuates thrombin-
induced ERK2 activity and VSMC proliferation. Furthermore,
our results show that thrombin induces Hsp70 and Hsp90
expression in VSMC via activation of the JAK-STAT pathway.
Thus, the JAK-STAT pathway may be an important physiologic
mediator of thrombin-induced events in VSMC.
EXPERIMENTAL PROCEDURES
Materials—Thrombin and AG-490 were purchased from Calbiochem.
H9C2 cells were obtained from American Type Culture Collection.
Antibodies used are as follows: anti-JAK1, JAK2, TYK2, STAT1,
STAT2, STAT3, FLAG, and anti-phosphotyrosine (4G10) (Upstate Bio-
technology, Inc., Lake Placid, NY, and Santa Cruz Biotechnology, San
Diego, CA); anti-phosphospecific JAK2 (BIOSOURCE International,
Camarillo, CA); anti-phosphospecific and -nonphosphospecific ERK1/2
(New England Biolabs, Beverly, MA); anti-Hsp70 (Affinity BioRe-
agents, Golden, CO) and anti-Hsp90 (StressGen, Victoria, Canada).
[14C]Chloramphenicol (55 mCi/mmol), [methyl-3H]thymidine (70 Ci/
mmol), and [g-32P]ATP (3,000 Ci/mmol) were obtained from
PerkinElmer Life Sciences. Diphenyleneiodonium, N-acetyl-L-cysteine,
and pyrrolidine dithiocarbamate were obtained from Sigma.
Cell Culture—VSMC were isolated from the thoracic aortas of 200–
250-g male Harlan Sprague-Dawley rats (8). Cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10%
(v/v) calf serum, 100 units/ml penicillin, 100 mg/ml streptomycin at
37 °C in a humidified 95% air, 5% CO2 atmosphere. All experiments
were conducted using VSMC between passage numbers 7 and 20 that
were growth-arrested by incubation in DMEM containing 0.1% calf
serum for 72 h.
[3H]Thymidine Incorporation—VSMC, grown to ;70% confluence
in 60-mm dishes, were quiesced by incubating in DMEM containing
0.1% calf serum for 72 h. Quiesced VSMC were exposed to 1.0 unit/ml
thrombin for 24 h after pretreatment with a JAK2-specific inhibitor,
AG-490, for 16 h. Cells were labeled with [methyl-3H]thymidine for
4 h, and its incorporation into DNA was measured as described
previously (9).
Cell Proliferation Assay—VSMC were plated in 60-mm dishes at an
initial concentration of 3,500 cells/cm2 and grown in DMEM supple-
mented with 10% fetal bovine serum for 48 h. Cells were growth-
arrested by incubating in DMEM containing 0.1% calf serum for 48 h
and then either left untreated or exposed to AG-490 for 16 h before
treatment with 1.0 unit/ml thrombin for 48 h. The cells were washed
with phosphate-buffered saline, trypsinized, and diluted with isotonic
solution, and the increase in cell number was directly measured with a
Coulter counter (model ZM, Coulter Corp., Hialeah, FL).
Immunoprecipitation, ERK2 Activity Assay, and Western Blotting—
Growth-arrested VSMC were treated with 1.0 unit/ml thrombin in the
presence and absence of AG-490 for the specified times at 37 °C. The
cells were lysed in a buffer containing 20 mM HEPES, pH 7.4, 2 mM
EGTA, 1 mM dithiothreitol, 50 mM b-glycerophosphate, 1% Triton
X-100, 20 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mM sodium orthovana-
FIG. 1. Thrombin-induced VSMC DNA synthesis and prolifer-
ation is inhibited by AG-490. A, growth-arrested VSMC were pre-
treated with the JAK2-specific inhibitor, AG-490, for 16 h prior to
exposure to 1.0 unit/ml thrombin for 24 h. DNA synthesis is expressed
as [3H]thymidine incorporation in cpm/dish. Data represent the
means 6 S.D. of two experiments, each with four replicates. B, growth-
arrested VSMC were either left untreated or exposed to AG-490 for 16 h
before treatment with 1.0 unit/ml thrombin for 48 h. Increase in cell
number was directly measured with a Coulter counter. Data represent
the means 6 S.D. of two experiments, each with four replicates. The
asterisk represents significant differences compared with control, and
the double asterisks represent significant differences compared with
thrombin treatment (p , 0.05). DMSO, dimethyl sulfoxide.
FIG. 2. Thrombin activates JAK family kinases in rat VSMC. VSMC were growth-arrested for 72 h and treated with 1.0 unit/ml thrombin
for the indicated times. Cells were harvested in kinase lysis buffer, and lysates containing an equal amount of protein were immunoprecipitated
(IP) with anti-phosphotyrosine antibody (4G10). Western blot (WB) analysis was performed with anti-JAK1, anti-JAK2, or anti-TYK2 antibody.
The results presented are representative of an experiment that was repeated at least three times.
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date, and 400 mM phenylmethylsulfonyl fluoride (9). For immunopre-
cipitation, cell lysates containing equal amounts of proteins were incu-
bated with appropriate antibodies overnight at 4 °C. The antibody-
protein complexes were incubated with protein A-Sepharose CL-4B/
protein A/G plus agarose beads for 2 h at 4 °C, and antibody-protein
complexes bound to the beads were pelleted at 2,000 3 g for 2 min. The
beads were washed three times with lysis buffer and once with phos-
phate-buffered saline and resuspended in Laemmli sample buffer. The
samples were resolved on 7.5% SDS-polyacrylamide gels. ERK2 activity
assay and Western blotting were performed as described previously (9).
Electrophoretic Mobility Shift Assay—Nuclear extracts were prepa-
red from growth-arrested VSMC that were either treated or untreated
with thrombin (35). DNA binding was performed by incubating 5 mg of
nuclear protein in a total volume of 20 ml of reaction mixture containing
10 mM HEPES, pH 7.9, 50 mM KCl, 4% glycerol, 1 mM dithiothreitol, 1
mM EDTA, 1 mg of poly(dI-dC), and 100,000 cpm of 32P-labeled double-
stranded Hsp70 (2122GATCCGGCGAAACCCCTGGAATATTCCCCGA-
CCT290) or Hsp90 (2643GCCTGGAAACTGCTGGAAAT2623) oligonu-
cleotide for 20 min at room temperature. Canonical double-stranded
oligonucleotides for SP1 (59-ATTCGATCGGGGCGGGGCGAGC-39) and
a high affinity double-stranded STAT1-binding sequence SIEm67 (59-
GATCTGATTACGGGAAATG-39) (36) were used in competition studies.
For identifying bands containing specific STAT proteins, the samples
were incubated with STAT1 or STAT3 antibody for 30 min before the
DNA-binding reaction was performed. Protein-DNA complexes were
resolved on a 4% polyacrylamide gel, and the dried gel was exposed to
X-Omat AR x-ray film with intensifying screen at 270 °Cz.
Transient Transfection of H9C2 Cells—Dominant negative JAK2
(DJAK2) that lacks the C-terminal kinase domain was kindly provided
by Dr. S. Watanabe (University of Tokyo) (37). H9C2 cells were grown
to 60–70% confluence in DMEM containing 10% fetal bovine serum and
were transfected with either 10 mg of control vector or DJAK2 and
FLAG-ERK2 (kindly provided by Dr. M. J. Weber, University of Vir-
ginia, Charlottesville, VA) plasmid DNA. Transient transfection was
done using FuGENE (Roche Molecular Biochemicals) according to the
manufacturer’s instructions. Cells were quiesced with DMEM contain-
FIG. 3. Rapid tyrosine phosphorylation of JAK2 and delayed
activation of TYK2 in VSMC treated with thrombin. Growth-
arrested VSMC were treated with 1.0 unit/ml thrombin for the indi-
cated times and harvested in lysis buffer. A, cell lysates containing
equal amounts of protein were analyzed by Western blotting (WB) with
anti-phosphotyrosine-specific JAK2 antibody (top). Thrombin had no
effect on JAK2 protein levels as observed in Western blot analysis with
anti-JAK2 antibody (bottom). B, densitometric analysis of JAK2 tyro-
sine phosphorylation (mean 6 S.D., n 5 3). C, cell lysates containing
equal amounts of protein were immunoprecipitated (IP) with anti-
TYK2 antibody, and Western analysis was performed with anti-phos-
photyrosine antibody (4G10) (top) or anti-TYK2 antibody (bottom). No
difference in TYK2 protein levels was observed in the Western blot
probed with anti-TYK2 antibody. D, densitometric analysis of TYK2
tyrosine phosphorylation (mean 6 S.D., n 5 3).
FIG. 4. Thrombin induces tyrosine phosphorylation and nu-
clear translocation of STAT1 and STAT3. Growth-arrested VSMC
were treated with 1.0 unit/ml thrombin for the indicated times, and cell
lysates were prepared. A, cell lysates with equal amounts of protein
were immunoprecipitated (IP) with anti-phosphotyrosine antibody, and
Western blot (WB) analysis was performed with anti-STAT1 antibody.
B, nuclear (top) or cytosolic (bottom) fractions prepared from thrombin-
treated VSMC, containing equal amounts of protein, were analyzed by
Western blotting with anti-STAT1 antibody. C, densitometric analysis
of nuclear translocated STAT1 p84/p91 protein levels (mean 6 S.D., n 5
3). D, lysates containing equal amounts of protein were immunoprecipi-
tated with anti-phosphotyrosine antibody and analyzed by Western
blotting with anti-STAT3 antibody. E, lysates containing equal
amounts of protein were analyzed by Western blotting with anti-phos-
photyrosine-specific STAT3 antibody. F, nuclear (top) or cytosolic (bot-
tom) fractions from thrombin-treated VSMC containing equal amounts
of protein were analyzed by Western blotting with anti-STAT3 anti-
body. G, densitometric analysis of nuclear translocated STAT3 protein
levels (mean 6 S.D., n 5 3).
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ing 0.1% calf serum 24 h after transfection. After quiescing for 20 h,
cells were treated with 1.0 unit/ml thrombin for the indicated times.
Transient Transfection and CAT Assay—The Hsp70 CAT reporter
constructs LSN (2188 to 11) and LSNP (2100 to 11) were kindly
provided by Richard Morimoto (Northwestern University, Evanston,
IL). The 59 Hsp90b CAT reporter constructs A (21044 to 136) and C
(2299 to 136) were kindly provided by David Latchman (University
College London, London, UK). For transfection, VSMC were grown to
70–80% confluence in 100-mm dishes containing DMEM with 10% fetal
bovine serum. Transfection of VSMC with Hsp90b CAT reporter and
DJAK2 plasmid DNA was performed by the calcium precipitate method
(9). Cells were cotransfected with b-galactosidase expression vector to
normalize for transfection efficiency. Cells were quiesced with DMEM
containing 0.1% calf serum 16 h after transfection. After being quies-
cent for 36 h, cells were either untreated or treated with thrombin for
6 h. In experiments with AG-490, cells were treated with the inhibitor
for 16 h before thrombin treatment. Cell lysates were prepared as
described previously (9), and CAT activity was measured (38). In brief,
100 mg of protein was incubated with 4 ml of 40 mM acetyl-CoA and 4 ml
of 50 mCi/ml [C14]chloramphenicol in a total volume of 150 ml at 37 °C
for 2–4 h. Acetylated and nonacetylated chloramphenicol were ex-
tracted with ethyl acetate and separated by thin layer chromatography
on Silica Gel 1B plates using chloroform/methanol mixture (19:1) as
solvent. Air-dried silica plates were subjected to autoradiography, and
the acetylated [C14]chloramphenicol was quantified using an Instant
Imager (Packard Instrument Co.). b-Galactosidase assay was per-
formed following manufacturer’s protocol (Promega).
Statistical Analysis—Differences were analyzed with one-way anal-
ysis of variance, and post-hoc analysis was performed using Student-
Newman-Keuls method. Values of p , 0.05 were considered statisti-
cally significant.
RESULTS
Thrombin-induced Mitogenesis Is Inhibited by AG-490—To
understand the role of tyrosine phosphorylation in thrombin-
induced VSMC mitogenesis, we have investigated the effect of
thrombin on the JAK-STAT pathway. Initially, growth-ar-
rested rat VSMC were treated with 1.0 unit/ml thrombin in the
presence and absence of AG-490, a specific inhibitor of JAK2.
As shown in Fig. 1A, thrombin induced a 4.6-fold increase in
DNA synthesis as measured by thymidine uptake after 24 h, an
effect that was significantly inhibited in a dose-dependent
manner by AG-490 (p , 0.05). AG-490 per se had no significant
effect on DNA synthesis even at a concentration of 50 mM.
Measuring its effect on cell counts corroborated the inhibi-
tory effect of AG-490 on thrombin-induced DNA synthesis.
AG-490 significantly inhibited the thrombin-induced increase
in VSMC proliferation in a dose-dependent manner (Fig. 1B,
p , 0.05). AG-490 alone had no significant effect on VSMC
proliferation, indicating that it is not cytotoxic at the concen-
trations used in this experiment. AG-490 also significantly
inhibited PAR-1-derived agonist peptide (SFLLRNP)-induced
VSMC DNA synthesis (not shown) suggesting that the effects
of thrombin-induced JAK2 activation are mediated via PAR-1
activation. The effect of AG-490 on thrombin-induced VSMC
proliferation is similar to its effect on VSMC growth induced by
Ang II, another G protein-coupled receptor agonist (10). These
results suggest that JAK2 plays a role in VSMC proliferation
induced by the activation of G protein-coupled receptors and
led us to test the activation of specific members of the JAK-
STAT pathway in response to thrombin stimulation.
Thrombin Stimulates JAK2 and TYK2 Kinase Activity in Rat
VSMC—To assess the contributions of the different JAK ki-
nases to thrombin-induced tyrosine phosphorylation, we immu-
noprecipitated tyrosine-phosphorylated proteins after throm-
bin stimulation and probed for the presence of phosphorylated
JAK proteins (Fig. 2). By using an anti-JAK1 antibody, we
found that JAK1 was transiently phosphorylated at 15 min
after stimulation with thrombin (Fig. 2). In contrast, we ob-
served a biphasic increase in JAK2 tyrosine phosphorylation
following treatment with thrombin (Fig. 2). This was confirmed
by Western blot analysis of thrombin-stimulated cell lysates
with a phospho-specific JAK2 antibody (Fig. 3A), which dem-
onstrated maximal stimulation of JAK2 at 1 min (8.7 6 4.0-fold
increase) (Fig. 3B). Finally, we also measured thrombin-in-
duced TYK2 phosphorylation (Fig. 2). In contrast to the rapid
activation of JAK2, peak activation of TYK2 was observed after
15 min of exposure to thrombin. These results were corrobo-
rated by additional experiments in which thrombin-stimulated
VSMC lysates were immunoprecipitated with an anti-TYK2
antibody and analyzed by Western blotting with the mono-
clonal anti-phosphotyrosine antibody (Fig. 3C). TYK2 tyrosine
phosphorylation was maximum (5.0 6 1.0-fold increase) at 15
min after thrombin stimulation (Fig. 3D). JAK3 protein was
not observed in VSMC lysates, which is consistent with reports
that the expression of this protein is confined to lymphoid and
myeloid cells (39, 40). The differences in the time course of
tyrosine phosphorylation of various JAKs suggest that they
may participate in different stress-mediated events in VSMC.
FIG. 5. AG-490 causes partial inhibi-
tion of thrombin-induced ERK1/2 ac-
tivation. Growth-arrested VSMC were
pretreated with AG-490 for 16 h and then
treated with 1.0 unit/ml thrombin for the
indicated times. A, cell lysates containing
equal amounts of protein were analyzed
by Western blotting (WB) with phos-
phospecific anti-ERK1/2 antibody. B, ly-
sates containing equal amounts of protein
were immunoprecipitated with anti-
ERK2 antibody. ERK2 activity was meas-
ured through immunocomplex kinase as-
say using myelin basic protein (MBP) as a
substrate. C, Western blot analysis of cell
lysates with anti-ERK1/2 antibody did
not show any difference in ERK1/2 pro-
tein levels. Results shown represent an
experiment that was repeated at least
twice with similar results. DMSO, di-
methyl sulfoxide.
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The increase in tyrosine phosphorylation of JAK2 and TYK2
in response to thrombin treatment was not due to an increase
in the levels of these protein as determined by Western blotting
(Fig. 3, A and C), indicating that thrombin altered tyrosine
phosphorylation of JAKs without affecting steady-state protein
levels. Similar to the observation of Abe and Berk (41), pre-
treatment of VSMC with 50 mM AG-490 for 16 h completely
inhibited thrombin-induced tyrosine phosphorylation of JAK2,
whereas it had no effect on c-Src, a non-JAK cytosolic tyrosine
kinase (not shown). Because JAK2 phosphorylation was most
pronounced following treatment with thrombin and inhibition
of the JAK2 phosphorylation with AG-490 blocked thrombin-
induced proliferation of VSMC, we chose to investigate further
the role of JAK2 in thrombin-induced mitogenesis.
Thrombin-induced JAK2 Activation Leads to Tyrosine Phos-
phorylation and Nuclear Translocation of STAT1, STAT2, and
STAT3 in Rat VSMC—To determine whether thrombin-in-
duced JAK2 activation leads to tyrosine phosphorylation of
STAT proteins, the JAK substrates, we measured tyrosine
phosphorylation and nuclear translocation of these proteins.
First, thrombin-treated VSMC lysates were immunoprecipi-
tated with an anti-phosphotyrosine antibody, and the Western
blots were probed with polyclonal antibodies against
STAT1a/b, STAT2, or STAT3. All three STAT proteins were
tyrosine-phosphorylated in response to thrombin treatment.
STAT1a was rapidly tyrosine-phosphorylated within 1 min, an
effect that was sustained for 60 min (Fig. 4A). The increase in
tyrosine phosphorylation of STAT1b in response to treatment
with thrombin was much less pronounced than that of STAT1a.
To determine whether tyrosine phosphorylation of STAT pro-
teins in response to treatment with thrombin was accompanied
by translocation into the nucleus, Western blot analyses of
nuclear and cytosolic fractions of thrombin-treated VSMC were
performed (Fig. 4B). Thrombin induced nuclear translocation of
STAT1 in 5 min (3.03 6 0.25-fold increase), an increase that
was sustained for 60 min (Fig. 4C), whereas no discernible
change was observed in the protein levels in cytosolic fractions
(Fig. 4D).
Immunoprecipitation/immunoblotting experiments revealed
an increase in tyrosine phosphorylation of STAT3 within 1 min
in response to treatment with thrombin that was sustained
throughout the 60-min treatment period (Fig. 4, D and E). As
with STAT1, STAT3 also rapidly translocated to the nucleus
FIG. 6. AG-490 inhibits thrombin-induced JAK2 phosphoryla-
tion and ERK2 activation. A, growth-arrested VSMC were pre-
treated with various concentrations of AG-490 for 16 h and then treated
with 1.0 unit/ml thrombin for 1 min. Cell lysates containing equal
amounts of protein were analyzed by Western blotting (WB) with anti-
phosphotyrosine-specific JAK2 antibody. B, ERK2 activity was meas-
ured from lysates of cells treated with thrombin for 60 min in the
presence and absence of AG-490 as described for Fig. 5. C, growth-
arrested VSMC were pretreated with 50 mM AG-490 for 16 h and then
treated with 1.0 unit/ml thrombin, 10% fetal bovine serum, or 1 mM
PMA for 5 min. ERK2 activity was measured as described above. MBP,
myelin basic protein; DMSO, dimethyl sulfoxide.
FIG. 7. Dominant negative JAK2 (DJAK2) inhibits thrombin-
induced ERK2 activation. H9C2 cells were transfected with either
vector control or DJAK2 and FLAG-ERK2 plasmids. Cells were grown
in DMEM supplemented with 10% fetal bovine serum for 36 h and
growth-arrested for 20 h. Cells were treated with 1.0 unit/ml thrombin
for the indicated times, and lysates containing equal amounts of protein
were analyzed by Western blotting (WB) with anti-JAK2 antibody (A).
B, lysates containing equal amounts of protein were immunoprecipi-
tated (IP) with anti-FLAG antibody, and Western blotting was per-
formed with anti-ERK2 antibody (C). ERK2 activity was measured in
cell lysates immunoprecipitated with anti-FLAG antibody as described
for Fig. 5. MBP, myelin basic protein. D, densitometric analysis of
ERK2 activity (mean 6 S.D., n 5 3). The asterisk represents significant
difference compared with control, and the double asterisks represent
significant differences compared with thrombin treatment (p , 0.05).
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following treatment with thrombin, whereas the levels of this
protein in cytosolic fractions were similar to control values (Fig.
4F). Peak nuclear translocation of STAT3 protein was observed
at 10 min after treatment with thrombin (6.63 6 1.52-fold
increase) (Fig. 4G). Increased tyrosine phosphorylation and
nuclear translocation of STAT2 was also observed in VSMC
treated with 1.0 unit/ml thrombin (not shown). These experi-
ments demonstrate that thrombin causes tyrosine phosphoryl-
ation and nuclear translocation of STAT proteins in VSMC.
Inhibition of JAK2 tyrosine phosphorylation by pretreatment
of VSMC with 50 mM AG-490 for 16 h blocked tyrosine phos-
phorylation and nuclear translocation of STAT1, STAT2, and
STAT3 (not shown), indicating that JAK2 kinase activity is
required for phosphorylation of these proteins.
Inhibition of JAK2 Kinase Activity Partially Blocks ERK1/2
Activation in VSMC—Because JAK2 has been suggested to be
upstream of the MAP kinase cascade (10, 41, 42) and MAP
kinase activation is required for thrombin-induced DNA syn-
thesis in VSMC (8), we have investigated whether JAK2 acti-
vation is required for thrombin-induced stimulation of ERK1/2.
ERK1/2 activation was measured in Western blots using a
phospho-specific antibody and also by an immunocomplex ki-
nase assay. Consistent with our previous work (8), thrombin
activated ERK1/2 kinases in a biphasic manner with peaks at
5 and 60 min (Fig. 5, A and B). AG-490 markedly inhibited
thrombin-induced activation of ERK1/2 in Western blots (Fig.
5A) and ERK2 activity in immunocomplex kinase assays (Fig.
5B) (4.3 6 0.7 at 60 min versus 2.1 6 0.6 and 1.5 6 0.4 with 10
and 50 mM AG-490, respectively, p , 0.05). However, no detect-
able change was observed in the steady-state ERK1/2 protein
levels following treatment with thrombin, either in the pres-
ence or absence of AG-490 or with AG-490 alone (Fig. 5C).
AG-490 caused a concentration-dependent inhibition of throm-
bin-induced JAK2 phosphorylation (Fig. 6A) and ERK2 activa-
tion (Fig. 5B and 6B). In contrast, ERK2 activation induced by
1 mM phorbol 12-myristate 13-acetate (PMA) and 10% fetal
bovine serum was not significantly affected by 50 mM AG-490.
ERK activation in VSMC induced by PMA and serum is con-
sistent with the previous reports (9, 43). Together, these results
suggest that thrombin-induced JAK2 is specifically inhibited
by AG-490, and thrombin-induced ERK1/2 activation is par-
tially regulated through JAK2 kinase in VSMC.
It is possible that any given inhibitor may have pleiotropic
effects on cell physiology. Recently, AG-490 was shown to in-
hibit activation of JAK3 induced by interleukin-2 in antigen-
activated human T cells (44). However, we did not detect JAK3
in VSMC with or without thrombin treatment. To provide an
alternative demonstration of the role of JAK2 inhibition, H9C2
rat myoblast cells were transiently transfected with a domi-
nant negative JAK2, which lacks the kinase domain (37) and a
FLAG-ERK2. The rationale for using this clonal muscle cell
line instead of VSMC is the relative ease of transfection. As
expected, transfection of dominant negative JAK2 markedly
inhibited thrombin-induced JAK2 phosphorylation (Fig. 7A),
whereas a vector control had no such effect (not shown). Dom-
inant negative JAK2 transfection also had no effect on steady-
state ERK2 protein levels (Fig. 7B). Dominant negative JAK2
markedly reduced thrombin-induced FLAG-ERK2 activation
(4.40 6 0.53 versus 2.00 6 0.27 at 60 min of thrombin treat-
ment, p , 0.05) confirming the regulatory role of JAK2 in
thrombin-induced ERK2 activation (Fig. 7, C and D).
Antioxidants Inhibit Thrombin-stimulated JAK2 Phospho-
rylation—Reactive oxygen species (ROS)-dependent activation
of JAK2 has been reported in rat VSMC treated with Ang II
(45). Because thrombin also generates ROS in VSMC (58), we
investigated whether antioxidants inhibit thrombin-induced
activation of JAK2. Pretreatment of VSMC with various anti-
oxidants (diphenyleneiodonium, an inhibitor of flavin-contain-
ing enzymes, N-acetyl-L-cysteine, and pyrrolidine dithiocar-
bamate) significantly inhibited thrombin-induced JAK2
phosphorylation without affecting steady-state protein levels
(Fig. 8), indicating that one mechanism by which thrombin
induces JAK2 activation is via generation of ROS.
Thrombin-induced Heat Shock Protein (Hsp70 and Hsp90)
Expression Is Mediated through the Activation of the JAK-
STAT Pathway—G protein-coupled receptor agonists such as
Ang II (46) and thrombin (9) and receptor tyrosine kinase
agonists such as platelet-derived growth factor-BB (PDGF-BB)
(47) are known to regulate VSMC proliferation through the
induction of ROS. Accumulation of Hsps has been reported in
cardiac tissue during ischemia and reperfusion, conditions
known to produce ROS (48, 49). In addition, Hsp70 and Hsp90b
promoters contain functional STAT-binding sites (50). There-
fore, we investigated whether treatment of VSMC with throm-
bin leads to the accumulation of these proteins. Thrombin-
stimulated expression of Hsp70 protein was evident at 2 h, and
a 3.36 6 0.78-fold increase was observed at 24 h (Fig. 9A).
Pretreatment of VSMC with 50 mM AG-490 prior to exposure to
thrombin abolished the agonist-induced increase in Hsp70
steady-state protein levels (3.50 6 0.50 versus 1.30 6 0.17, p ,
0.05) (Fig. 9B). A biphasic increase in Hsp90 protein levels was
also observed in VSMC in response to thrombin, with an initial
peak at 4 h (2.46 6 0.74-fold increase), and a second peak at
24 h (3.87 6 0.71-fold increase) (Fig. 9C). As with Hsp70,
increased levels of Hsp90 were ablated in response to the
inhibition of JAK2 tyrosine phosphorylation with 50 mM AG-
490 (3.67 6 0.83 versus 1.33 6 0.06, p , 0.05) (Fig. 9D).
FIG. 8. ROS mediate thrombin-induced JAK2 tyrosine phos-
phorylation. Growth-arrested VSMC were pretreated with 10 mM di-
phenyleneiodonium (DPI), 100 mM pyrrolidine dithiocarbamate (PDTC),
or 10 mM N-acetyl-L-cysteine (NAC) for 30 min and then treated with
1.0 unit/ml thrombin for 1 min. Lysates containing equal amounts of
protein were analyzed by Western blotting (WB) with either anti-phos-
photyrosine-specific JAK2 (A) or JAK2 (B) antibody. C, densitometric
analysis of JAK2 tyrosine phosphorylation (mean 6 S.D., n 5 3).
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AG-490, by itself, had no marked effect on Hsp70 and Hsp90
protein levels.
Next, we investigated whether induction of Hsp70 and
Hsp90 in thrombin-treated VSMC is mediated via the tran-
scriptional activity of the STAT proteins. For this, an electro-
phoretic mobility shift assay was performed by incubating nu-
clear proteins from thrombin-treated VSMC with a synthetic
Hsp70-STAT oligonucleotide corresponding to 2122 to 290
base pairs of the Hsp70 promoter. Three shifted bands were
observed with nuclear extracts from thrombin-treated VSMC,
each of which was competed with an excess of unlabeled spe-
cific oligonucleotide, but not with a nonspecific one (Fig. 10).
The faster migrating two bands were partially abolished by
preincubation of complexes with either anti-STAT1 or anti-
STAT3 antibodies, indicating that these complexes likely con-
tain STAT1/STAT3 heterodimers. The slower migrating band
was abolished by anti-STAT1 antibody, but not by anti-STAT3
antibody, demonstrating the presence of STAT1 protein in this
complex. Electrophoretic mobility shift assay of VSMC nuclear
extracts with the STAT-binding region of Hsp90b synthetic
oligonucleotide (2643 to 2623 of Hsp90b promoter) demon-
strated two shifted bands, the intensity of which was enhanced
in response to thrombin (Fig. 11). The bands were competed
with an excess of unlabeled specific oligonucleotide but not
with a nonspecific one. The faster migrating band was com-
peted with an unlabeled high affinity STAT1-binding sequence
(SIEm67 oligonucleotide) from the c-fos promoter and was abol-
ished by addition of an anti-STAT1 antibody. In contrast, the
slower migrating band was abolished by anti-STAT3 antibody
but not by anti-STAT1 antibody. These results indicate that
the faster migrating band has STAT1 protein and the slower
migrating band has STAT3 protein in the complex. None of the
antibodies tested produced supershifts in electrophoretic mo-
bility shift assays.
Activation of the Hsp90b Promoter by Thrombin Is JAK2-de-
pendent—To investigate whether thrombin-induced Hsp90 ex-
pression was mediated via a direct effect of activated STAT
proteins on its promoter, VSMC were transfected with an
Hsp90b promoter-reporter construct either containing Hsp90 A
(21044 to 136) or lacking Hsp90 C (2299 to 136), a functional
STAT-binding site. The Hsp90 A construct, besides possessing
a STAT3-like binding site, also binds activated STAT1 protein
(50). The reporter construct Hsp90 A was activated 2–4-fold by
thrombin, whereas deletion of sequences containing the func-
tional STAT-binding site abolished the activation of this pro-
moter by thrombin (Fig. 12A). Thrombin-induced Hsp90b pro-
moter activity was also abolished in VSMC pretreated with 50
mM AG-490, indicating that phosphorylation of STAT proteins
by JAK2 kinase is necessary for maximal promoter activity
(Fig. 12B). To confirm the role of JAK-STAT pathway in throm-
bin-induced Hsp90 expression, VSMC were cotransfected with
Hsp90 A promoter-reporter construct and a dominant negative
JAK2. Again, thrombin-induced Hsp90b promoter activity was
completely abolished in the presence of dominant negative
JAK2 (Fig. 12C). Together, these results indicate that the G
protein-coupled receptor agonist thrombin causes activation of
the JAK-STAT pathway in rat VSMC, and this pathway plays
an important role in thrombin-induced VSMC proliferation and
expression of proliferation-associated Hsps.
DISCUSSION
Thrombin-mediated tyrosine phosphorylation of various pro-
teins such as insulin-like growth factor-1 receptor (8) and epi-
dermal growth factor receptor (51) has been attributed to the
activation of cytosolic tyrosine kinase, c-src. Stimulation of the
Ras/MAP kinase pathway by the activation of G protein-cou-
pled receptors has also been linked to Src kinases (14). In
contrast, we show that JAK2, a non-Src family cytosolic tyro-
FIG. 9. AG-490 inhibits thrombin-induced Hsp70 and Hsp90 protein levels. A, growth-arrested VSMC were treated with 1.0 unit/ml
thrombin for the indicated times, and Hsp70 protein levels were analyzed by Western blotting with anti-Hsp70 antibody (top). Densitometric
analysis of Hsp70 protein levels was performed (mean 6 S.D., n 5 3) (bottom). B, cells were pretreated with AG-490 for 16 h and treated with
thrombin for 24 h (top). Cell lysates containing equal amounts of protein were analyzed by Western blotting (WB) with anti-Hsp70 antibody.
Densitometric analysis of Hsp70 protein levels was done (mean 6 S.D., n 5 3) (bottom). C, cell lysates from growth-arrested VSMC treated with
1.0 unit/ml thrombin for the indicated times were analyzed by Western blotting with anti-Hsp90 antibody (top). Densitometric analysis of Hsp90
protein levels was performed (mean 6 S.D., n 5 3) (bottom). D, cells were pretreated with AG-490 for 16 h and treated with thrombin for 24 h. Cell
lysates containing equal amounts of protein were analyzed by Western blotting with anti-Hsp90 antibody (top). Densitometric analysis of Hsp90
protein levels was done (mean 6 S.D., n 5 3) (bottom). The asterisk represents significant difference compared with control, and the double
asterisks represent significant differences compared with thrombin treatment (p , 0.05). DMSO, dimetyl sulfoxide.
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sine kinase, is involved in thrombin-induced activation of
ERK1/2 kinases, VSMC proliferation, and expression of Hsp70
and Hsp90.
The involvement of JAK kinases in signaling pathways in-
duced by the activation of cytokine receptors and receptor
tyrosine kinases is well documented (16, 53). Recently, it was
shown that activation of the G protein-coupled receptor, Ang II
AT1, leads to phosphorylation of tyrosine 319 in the C-terminal
intracellular domain and subsequent binding of SHP-2 phos-
photyrosine phosphatase and the JAK2 tyrosine kinase com-
plex (54). This suggests that G protein-coupled receptors pos-
sess mechanisms similar to those of cytokine and growth factor
receptors for signal transduction involving cytosolic tyrosine
kinases such as JAK2. Here we demonstrate that thrombin
causes JAK2 and TYK2 activation in rat VSMC, and we have
investigated the role of JAK2 in thrombin-induced cellular
signaling using a specific pharmacologic inhibitor of JAK2.
AG-490 inhibited both thrombin and PAR-1-derived peptide-
induced DNA synthesis in VSMC. In addition, JAK2 coprecipi-
tates with PAR-1 in VSMC treated with thrombin,2 suggesting
a physical association between JAK2 and PAR-1. It remains to
be determined whether the association of JAK2 with PAR-1 is
similar to that described between JAK2 and Ang II AT1.
We found JAK2-dependent rapid tyrosine phosphorylation
and nuclear translocation of STAT1, STAT2, and STAT3 pro-
teins in VSMC. Tyrosine phosphorylation of STATs was also
reported in Ang II-treated VSMC (25). In agreement with our
findings, Ang II-induced STAT1 tyrosine phosphorylation is
mediated by JAK2 (54). Recently, it has been shown that JAK2,
TYK2, and STATs are also activated in response to oxidants in
several cell types, including VSMC ((41, 55, 56).2 We and others
(47, 57, 58) have demonstrated that growth factors such as
PDGF-BB and G protein-coupled receptor agonists such as Ang
II and thrombin stimulate VSMC growth through the produc-
tion of ROS. We also found that JAK2 activation induced by
thrombin is sensitive to antioxidants. Similar results with
regards to JAK2 sensitivity to antioxidants were reported
recently in VSMC treated with Ang II (45). Together these re-
sults suggest that in addition to receptor-associated stimulation,
another possible mechanism for the activation of JAK-STAT
pathway by thrombin is via the generation of intracellular ROS.
A biphasic increase in ERK1/2 activity was observed in rat
VSMC treated with thrombin. Inhibition of JAK2 activity by
AG-490 pretreatment partially inhibits thrombin-induced
ERK1/2 activity. This is in contrast to the complete inhibition
of ERK1/2 phosphorylation by AG-490 in VSMC treated with
either Ang II or PDGF-BB (10). This inhibition of ERK1/2
activity was shown to be a consequence of the inhibitory effect
of AG-490 on JAK2 stimulation, blocking the association be-
2 N. R. Madamanchi, S. Li, C. Patterson, and M. S. Runge, unpub-
lished data.
FIG. 10. Thrombin induces DNA binding of Hsp70 STAT se-
quence. Nuclear extracts from VSMC, either untreated (1st lane 1) or
treated with 1.0 unit/ml thrombin for 10 min (2nd to 6th lanes), were
subjected to an electrophoretic mobility shift assay using a labeled
Hsp70 STAT probe. To determine specificity of Hsp70 STAT binding
complex, nuclear extracts were preincubated with unlabeled specific or
nonspecific competitors. The specific competitors used were 100-fold
molar excess of Hsp70 STAT (3rd lane), and the nonspecific competitor
was 100-fold molar excess of SP1 consensus oligonucleotide (4th lane).
For the characterization of protein components of thrombin-induced
binding complex, nuclear extracts were preincubated with anti-STAT1
(5th lane) or anti-STAT3 (6th lane) antibody.
FIG. 11. Thrombin induces DNA binding of Hsp90 STAT se-
quence. Nuclear extracts from VSMC, either untreated (1st lane) or
treated with 1.0 unit/ml thrombin for 10 min (2nd to 7th lanes), were
subjected to an electrophoretic mobility shift assay using a labeled
Hsp90 STAT probe. To determine specificity of Hsp90 STAT binding
complex, nuclear extracts were preincubated with unlabeled specific or
nonspecific competitors. The specific competitors used were 100-fold
molar excess of Hsp90 STAT and STAT1-inducible element (SIE) (3rd
and 4th lanes, respectively), and the nonspecific competitor was 100-
fold molar excess of SP1 consensus oligonucleotide (5th lane). For the
characterization of protein components of thrombin-induced binding
complex, nuclear extracts were preincubated with anti-STAT1 (6th
lane) or anti-STAT3 (7th lane) antibody (Ab).
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tween JAK2 and Raf1 and subsequent Raf1 tyrosine phospho-
rylation. Abe and Berk (41) reported that H2O2-mediated
ERK1/2 phosphorylation is partially dependent on JAK2 acti-
vation. Taken together, these results place JAK2 upstream of
Ras in the Ras/Raf/MEK/ERK pathway and, thus, implicate
JAK2 in regulation of early growth response genes and cell
proliferation. This argument is supported by a recent report
(59) that activation of p38 MAP kinase, another member of the
MAP kinase superfamily, is JAK2-dependent. Because inhibi-
tion of JAK2 stimulation only partially inhibits thrombin-in-
duced ERK1/2 activation, a parallel pathway may exist to ac-
tivate ERK1/2 in thrombin-treated cells similar to that
proposed for H2O2-treated fibroblasts (41). Cross-talk between
the JAK-STAT and ERK pathways suggests that inhibition of
JAK2 activity might block not only direct tyrosine phosphoryl-
ation but also serine phosphorylation of STATs by ERK1/2.
However, emerging evidence indicates that regulation of STAT
proteins by ERK1/2 depends on the nature of stimulus. In
contrast to the reports that maximal activation of transcription
by STATs requires serine phosphorylation by MAP kinases in
addition to tyrosine phosphorylation (22, 23), ERK1/2 activa-
tion has been shown to inhibit interleukin-6-induced JAK-
STAT signaling (60). Further experiments are required to de-
fine the role of ERK1/2 in thrombin-induced activation of
STATs.
Thrombin is known to stimulate generation of ROS, the
cellular effects of which are modulated by Hsps. We therefore
hypothesized that thrombin might induce Hsp production in
VSMC. This hypothesis was supported by previous reports
documenting the presence of functional STAT-binding sites in
Hsp70 and Hsp90 promoters (50). Our results demonstrate
time-dependent induction of Hsp70 and Hsp90 proteins in
thrombin-treated VSMC. Pretreatment with 50 mM AG-490
inhibits the induction of these proteins suggesting that Hsp
synthesis is regulated via the JAK-STAT pathway.
Although Hsps were initially characterized by their induc-
tion in response to stress, emerging evidence indicates that
these proteins play a role in cellular signaling and cell prolif-
eration (61). Abrogation of Hsp70 expression in tumor cells
inhibits cell proliferation and induces apoptosis (62). Prior in-
duction of Hsp70 has been shown to play a role in the resump-
tion of proliferation after acute heat treatment (63). Similarly
Hsp90 is known to interact with many signaling molecules,
particularly kinases and ligand-regulated transcription factors
(64, 65). Decreased Hsp90 protein levels have been linked to a
slow rate of cell division (66). More recently it was demon-
strated that Hsp90 plays a crucial role in the maturation and
regulation of eukaryotic translation initiation factor kinase
Gcn2 (67) and proper functioning of the centrosome (52). In-
duction of VSMC growth by ROS has been linked in part to
autocrine/paracrine effects of proteins, including Hsp90a and
cyclophilins (34). AlThough we have not addressed the role of
Hsps in VSMC growth, these reports suggest that Hsps are
likely to play a role in thrombin-induced VSMC proliferation.
Electrophoretic mobility shift assays demonstrate that
STAT1 and STAT1/STAT3 heterodimers recognize the STAT
binding domain of the Hsp70 promoter, whereas STAT1 and
STAT3 are the selective proteins that bind the STAT-binding
element of the Hsp90b promoter. Hsp70 and Hsp90b promoter
constructs containing functional STAT-binding sites are acti-
vated by thrombin, and pretreatment with AG-490 or cotrans-
fection with dominant negative JAK2 blocks the activity of
these promoters. This strongly suggests that JAK2-mediated
tyrosine phosphorylation is required for activation of the Hsp70
and Hsp90 promoters in VSMC. In close proximity to the STAT
binding regions, the Hsp70 and Hsp90b promoters also contain
binding sites for the stress-activated transcription factor,
HSF1 (50). Activation of HSF-1 has been reported in heart
tissue perfused with H2O2 (48). Therefore, a concomitant role
for HSF1 in thrombin-induced expression of Hsp70 and Hsp90
is possible in view of the stimulation of ROS in thrombin-
treated VSMC. Consistent with this hypothesis, overexpression
FIG. 12. JAK2 inactivation inhibits
thrombin-induced Hsp90 promoter
activity. AG-490 inhibits thrombin-in-
duced Hsp90 promoter activity. A, VSMC
were transiently transfected with an
Hsp90 CAT reporter construct containing
21044 to 136 (A) or lacking 2299 to 136
(C) STAT binding region, or vector lack-
ing any insert, growth-arrested, and were
either untreated or treated with thrombin
for 6 h. Cell lysates were prepared, and
lysates containing equal amounts of pro-
tein were assayed for CAT activity. To
normalize for transfection efficiency, cells
were also cotransfected with a b-galacto-
sidase construct. B, VSMC transfected
with Hsp90 CAT reporter constructs were
growth-arrested, pretreated with AG-490
for 16 h, and treated with thrombin in the
presence and absence of AG-490. C,
VSMC transfected with Hsp90 CAT re-
porter and either vector or DJAK2 DNA
were growth-arrested and treated with
thrombin for 6 h. Autoradiograms shown
represent an experiment that was re-
peated at least twice with similar results.
Fold activation shown is based on the
quantitation of radioactivity measured by
an Instant Imager. DMSO, dimethyl
sulfoxide.
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of STAT1 and HSF1 has an additive effect on Hsp70 promoter
activity in HepG2 cells, suggesting that protein-protein inter-
actions between these nuclear proteins may play a role in the
regulation of Hsp70 transcriptional activity (50).
In summary, we have shown that the JAK-STAT pathway
plays an important role in thrombin-induced VSMC prolifera-
tion. In addition, enhanced expression of Hsp70 and Hsp90 via
the JAK-STAT pathway indicates that this pathway modulates
cellular responses to generation of ROS in VSMC treated with
thrombin. Together with the extensive work done on the JAK-
STAT pathway in VSMC mitogenesis (10, 34, 41), our results
suggest that this pathway plays a significant role in the pro-
gression of pathophysiologic vascular diseases such as
atherosclerosis.
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1252–1262
53. Choudhury, G. G., Choudhury, N. G., and Abboud, H. E. (1998) J. Clin. Invest.
101, 2751–2760
54. Venema, R. C., Ju, H., Venema, V. J., Schieffer, B., Harp, J. B., Ling, B. N.,
Eaton, D. C., and Marrero, M. B. (1998) J. Biol. Chem. 273, 7703–7708
55. Simon, A. R., Rai, U., Fanburg, B. L., and Cochran, B. H. (1998) Am. J. Physiol.
275, C1640–C1652
56. Carballo, M., Conde, M., Bekay, R. E., Matin-Nieto, J., Camacho, M. J.,
Monteseirin, J., Conde, J., Bedoya, F. J., and Sobrino, F. (1999) J. Biol.
Chem. 274, 17580–17586
57. Zafari, A. M., Ushio-Fukai, M., Akers, M., Yin, Q., Shah, A., Harrison, D. G.,
Taylor, W. R., and Griendling, K. K. (1998) Hypertension 32, 488–495
58. Patterson, C., Ruef, J., Madamanchi, N. R., Barry-Lane, P., Hu, Z., Horaist, C.,
Ballinger, A., Brasier, A. R., Bode, C., and Runge, M. S. (1999) J. Biol.
Chem. 274, 19814–19822
59. Zhu, T., and Lobie, P. E. (2000) J. Biol. Chem. 275, 2103–2114
60. Sengupta, T. K., Talbot, E. S., Scherle, P. A., and Ivashkiv, L. B. (1998) Proc.
Natl. Acad. Sci. U. S. A. 965, 11107–11112
61. Morano, K. A., and Thiele, D. J. (1999) Gene Expr. 7, 271–282
62. Wei, Y. Q., Zhao, X., Kariya, Y., Teshigawara, K., and Uchida, A. (1995) Cancer
Immunol. Immunother. 40, 73–78
63. van Dongen, G., and van Wijk, R. (1988) Radiat. Res. 113, 252–267
64. Aligue, R., Akhavan-Niak, H., and Russell, P. (1994) EMBO J. 13, 6099–6106
65. Pratt, W. B. (1998) Proc. Soc. Exp. Biol. Med. 217, 420–434
66. Galea-Lauri, J., Latchman, D. S., and Katz, D. R. (1996) Exp. Cell Res. 226,
243–254
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